Association Between Increased Linezolid Plasma Concentrations and the Development of Severe Toxicity in Multidrug-Resistant Tuberculosis Treatment

Treatment of multidrug-resistant (MDR) tuberculosis with linezolid is characterized by high rates of adverse events. Evidence on therapeutic drug monitoring to predict drug toxicity is scarce. This study aimed to evaluate the association of linezolid trough concentrations with severe toxicity. We re...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clinical infectious diseases Ročník 76; číslo 3; s. e947
Hlavní autoři: Eimer, Johannes, Fréchet-Jachym, Mathilde, Le Dû, Damien, Caumes, Eric, El-Helali, Najoua, Marigot-Outtandy, Dhiba, Mechai, Frédéric, Peytavin, Gilles, Pourcher, Valérie, Rioux, Christophe, Yazdanpanah, Yazdan, Robert, Jérôme, Guglielmetti, Lorenzo
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 08.02.2023
Témata:
Antitubercular Agents - adverse effects
Drug Monitoring
Humans
Linezolid - adverse effects
Retrospective Studies
Tuberculosis, Multidrug-Resistant - drug therapy
toxicity
severe adverse events
linezolid
multidrug-resistant tuberculosis
therapeutic drug monitoring
ISSN:1537-6591, 1537-6591
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Treatment of multidrug-resistant (MDR) tuberculosis with linezolid is characterized by high rates of adverse events. Evidence on therapeutic drug monitoring to predict drug toxicity is scarce. This study aimed to evaluate the association of linezolid trough concentrations with severe toxicity. We retrospectively assessed consecutive patients started on linezolid for MDR tuberculosis between 2011 and 2017. The primary outcome was severe mitochondrial toxicity (SMT) due to linezolid, defined as neurotoxicity or myelotoxicity leading to drug discontinuation. The impact of plasma linezolid trough concentrations >2 mg/L was assessed in multivariate Cox proportional hazards models including time-varying covariates. SMT occurred in 57 of 146 included patients (39%) at an incidence rate of 0.38 per person-year (95% confidence interval, .30-.49). A maximum linezolid trough concentration >2 mg/L was detected in 52 patients (35.6%), while the mean trough concentration was >2 mg/L in 22 (15%). The adjusted hazard ratio for SMT was 2.35 (95% confidence interval, 1.26-4.38; P = .01) in patients with a mean trough concentration >2 mg/L and 2.63 (1.55-4.47; P < .01) for SMT after the first detection of a trough concentration >2 mg/L. In an exploratory analysis, higher maximum trough concentrations were dose-dependently associated with toxicity, while lowering elevated trough concentrations did not restore baseline risk. Linezolid trough concentrations >2 mg/L are strongly associated with the development of severe treatment-emergent toxicity in patients treated for MDR tuberculosis. Pending further prospective evidence, an individual risk-benefit assessment on the continuation of linezolid treatment is warranted in any patient with trough concentrations >2 mg/L.
AbstractList Treatment of multidrug-resistant (MDR) tuberculosis with linezolid is characterized by high rates of adverse events. Evidence on therapeutic drug monitoring to predict drug toxicity is scarce. This study aimed to evaluate the association of linezolid trough concentrations with severe toxicity.BACKGROUNDTreatment of multidrug-resistant (MDR) tuberculosis with linezolid is characterized by high rates of adverse events. Evidence on therapeutic drug monitoring to predict drug toxicity is scarce. This study aimed to evaluate the association of linezolid trough concentrations with severe toxicity.We retrospectively assessed consecutive patients started on linezolid for MDR tuberculosis between 2011 and 2017. The primary outcome was severe mitochondrial toxicity (SMT) due to linezolid, defined as neurotoxicity or myelotoxicity leading to drug discontinuation. The impact of plasma linezolid trough concentrations >2 mg/L was assessed in multivariate Cox proportional hazards models including time-varying covariates.METHODSWe retrospectively assessed consecutive patients started on linezolid for MDR tuberculosis between 2011 and 2017. The primary outcome was severe mitochondrial toxicity (SMT) due to linezolid, defined as neurotoxicity or myelotoxicity leading to drug discontinuation. The impact of plasma linezolid trough concentrations >2 mg/L was assessed in multivariate Cox proportional hazards models including time-varying covariates.SMT occurred in 57 of 146 included patients (39%) at an incidence rate of 0.38 per person-year (95% confidence interval, .30-.49). A maximum linezolid trough concentration >2 mg/L was detected in 52 patients (35.6%), while the mean trough concentration was >2 mg/L in 22 (15%). The adjusted hazard ratio for SMT was 2.35 (95% confidence interval, 1.26-4.38; P = .01) in patients with a mean trough concentration >2 mg/L and 2.63 (1.55-4.47; P < .01) for SMT after the first detection of a trough concentration >2 mg/L. In an exploratory analysis, higher maximum trough concentrations were dose-dependently associated with toxicity, while lowering elevated trough concentrations did not restore baseline risk.RESULTSSMT occurred in 57 of 146 included patients (39%) at an incidence rate of 0.38 per person-year (95% confidence interval, .30-.49). A maximum linezolid trough concentration >2 mg/L was detected in 52 patients (35.6%), while the mean trough concentration was >2 mg/L in 22 (15%). The adjusted hazard ratio for SMT was 2.35 (95% confidence interval, 1.26-4.38; P = .01) in patients with a mean trough concentration >2 mg/L and 2.63 (1.55-4.47; P < .01) for SMT after the first detection of a trough concentration >2 mg/L. In an exploratory analysis, higher maximum trough concentrations were dose-dependently associated with toxicity, while lowering elevated trough concentrations did not restore baseline risk.Linezolid trough concentrations >2 mg/L are strongly associated with the development of severe treatment-emergent toxicity in patients treated for MDR tuberculosis. Pending further prospective evidence, an individual risk-benefit assessment on the continuation of linezolid treatment is warranted in any patient with trough concentrations >2 mg/L.CONCLUSIONSLinezolid trough concentrations >2 mg/L are strongly associated with the development of severe treatment-emergent toxicity in patients treated for MDR tuberculosis. Pending further prospective evidence, an individual risk-benefit assessment on the continuation of linezolid treatment is warranted in any patient with trough concentrations >2 mg/L.
Treatment of multidrug-resistant (MDR) tuberculosis with linezolid is characterized by high rates of adverse events. Evidence on therapeutic drug monitoring to predict drug toxicity is scarce. This study aimed to evaluate the association of linezolid trough concentrations with severe toxicity. We retrospectively assessed consecutive patients started on linezolid for MDR tuberculosis between 2011 and 2017. The primary outcome was severe mitochondrial toxicity (SMT) due to linezolid, defined as neurotoxicity or myelotoxicity leading to drug discontinuation. The impact of plasma linezolid trough concentrations >2 mg/L was assessed in multivariate Cox proportional hazards models including time-varying covariates. SMT occurred in 57 of 146 included patients (39%) at an incidence rate of 0.38 per person-year (95% confidence interval, .30-.49). A maximum linezolid trough concentration >2 mg/L was detected in 52 patients (35.6%), while the mean trough concentration was >2 mg/L in 22 (15%). The adjusted hazard ratio for SMT was 2.35 (95% confidence interval, 1.26-4.38; P = .01) in patients with a mean trough concentration >2 mg/L and 2.63 (1.55-4.47; P < .01) for SMT after the first detection of a trough concentration >2 mg/L. In an exploratory analysis, higher maximum trough concentrations were dose-dependently associated with toxicity, while lowering elevated trough concentrations did not restore baseline risk. Linezolid trough concentrations >2 mg/L are strongly associated with the development of severe treatment-emergent toxicity in patients treated for MDR tuberculosis. Pending further prospective evidence, an individual risk-benefit assessment on the continuation of linezolid treatment is warranted in any patient with trough concentrations >2 mg/L.
Author Guglielmetti, Lorenzo
Le Dû, Damien
Caumes, Eric
Yazdanpanah, Yazdan
Pourcher, Valérie
Marigot-Outtandy, Dhiba
El-Helali, Najoua
Peytavin, Gilles
Robert, Jérôme
Fréchet-Jachym, Mathilde
Mechai, Frédéric
Eimer, Johannes
Rioux, Christophe
Author_xml – sequence: 1
  givenname: Johannes
  orcidid: 0000-0002-3351-8581
  surname: Eimer
  fullname: Eimer, Johannes
  organization: INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Équipe 2, Sorbonne Université, Paris, France
– sequence: 2
  givenname: Mathilde
  surname: Fréchet-Jachym
  fullname: Fréchet-Jachym, Mathilde
  organization: Sanatorium, Centre Hospitalier de Bligny, Briis-sous-Forges, France
– sequence: 3
  givenname: Damien
  surname: Le Dû
  fullname: Le Dû, Damien
  organization: Sanatorium, Centre Hospitalier de Bligny, Briis-sous-Forges, France
– sequence: 4
  givenname: Eric
  surname: Caumes
  fullname: Caumes, Eric
  organization: Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, AP-HP.Sorbonne Université, Paris, France
– sequence: 5
  givenname: Najoua
  surname: El-Helali
  fullname: El-Helali, Najoua
  organization: Plateforme de Dosage des Anti-infectieux, Groupe Hospitalier Paris Saint-Joseph, Paris, France
– sequence: 6
  givenname: Dhiba
  surname: Marigot-Outtandy
  fullname: Marigot-Outtandy, Dhiba
  organization: AP-HP, Service de Maladies Infectieuses, Hôpital Raymond Poincaré, Université de Saint-Quentin en Yvelines, Garches, France
– sequence: 7
  givenname: Frédéric
  surname: Mechai
  fullname: Mechai, Frédéric
  organization: IAME INSERM UMR-S 1137, Hôpital Bichat-Claude Bernard, AP-HP, Paris, France
– sequence: 8
  givenname: Gilles
  surname: Peytavin
  fullname: Peytavin, Gilles
  organization: Laboratoire de Pharmacologie-Toxicologie, DMU Biologie et Génomique Médicale (BioGeM), IAME INSERM UMR-S 1137, Hôpital Bichat-Claude Bernard, AP-HP, Paris, France
– sequence: 9
  givenname: Valérie
  surname: Pourcher
  fullname: Pourcher, Valérie
  organization: Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, AP-HP.Sorbonne Université, Paris, France
– sequence: 10
  givenname: Christophe
  surname: Rioux
  fullname: Rioux, Christophe
  organization: AP-HP, Service de Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France
– sequence: 11
  givenname: Yazdan
  surname: Yazdanpanah
  fullname: Yazdanpanah, Yazdan
  organization: AP-HP, Service de Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France
– sequence: 12
  givenname: Jérôme
  surname: Robert
  fullname: Robert, Jérôme
  organization: Hôpital Pitié-Salpêtrière, Laboratoire de Bactériologie-Hygiène, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, AP-HP.Sorbonne Université, Paris, France
– sequence: 13
  givenname: Lorenzo
  surname: Guglielmetti
  fullname: Guglielmetti, Lorenzo
  organization: Hôpital Pitié-Salpêtrière, Laboratoire de Bactériologie-Hygiène, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, AP-HP.Sorbonne Université, Paris, France
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35717636$$D View this record in MEDLINE/PubMed
BookMark eNpNUE1PwzAMjdAQY4MTd5Qjl0LTJP04jvE1aQgE5Ty5qQdBbTKaFBg_g19MgCFxsOxnv_cse0QGxhok5IDFxywu-InSdQhQIpdbZJdJnkWpLNjgXz0kI-ee45ixPJY7ZMhlxrKUp7vkc-KcDWqvraGn6N8QDZ0Z1SE4rOlcG_ywja7pbQOuBTq1RqHx3Y_AUTA19U9Iz_AVG7tqw4jaJb0PsENa2nettF9Tbeh133hdd_1jdIdOOw-BWfYVdqpvbGjQMqz03wZ7ZHsJjcP9TR6Th4vzcnoVzW8uZ9PJPFK8YD4KFxQcmQSmlFB1teRcVlBVCvIsEaJWRcKrVKYsFTLPQS6TDFghYgUgQSmWjMnRr--qsy89Or9otVPYNGDQ9m6RpFkuEsFiEaiHG2pftVgvVp1uoVsv_v6YfAHHA3qR
CitedBy_id crossref_primary_10_7759_cureus_86248
crossref_primary_10_1128_aac_00294_25
crossref_primary_10_3390_pharmaceutics15112543
crossref_primary_10_1002_phar_2769
crossref_primary_10_1093_ofid_ofaf520
crossref_primary_10_1089_mdr_2024_0045
crossref_primary_10_1097_FTD_0000000000001343
crossref_primary_10_1016_j_ijantimicag_2024_107302
crossref_primary_10_1016_j_ijid_2024_01_001
crossref_primary_10_1097_FTD_0000000000001170
crossref_primary_10_1126_sciadv_adt5833
crossref_primary_10_1016_j_ccm_2023_06_012
crossref_primary_10_1128_asmcr_00087_24
crossref_primary_10_3390_ph16111575
crossref_primary_10_1128_aac_00034_24
crossref_primary_10_2147_IDR_S464429
crossref_primary_10_1038_s41586_025_09177_7
ContentType Journal Article
Contributor Bourgarit, Anne
Bonnet, Isabelle
Lecorché, Emmanuel
Mougari, Faiza
Morel, Florence
Tunesi, Simone
Veziris, Nicolas
Andrejak, Claire
Ellis-Corbet, Sophie
Roux, Anne-Laure
Escaut, Lelia
Alauzet, Corentine
Klement, Elise
Wicky, Marie
Rivoire, Bénédicte
Thouvenin, Guillaume
Aubry, Alexandra
Bernard, Christine
Jaspard, Marie
Contributor_xml – sequence: 1
  givenname: Alexandra
  surname: Aubry
  fullname: Aubry, Alexandra
– sequence: 2
  givenname: Isabelle
  surname: Bonnet
  fullname: Bonnet, Isabelle
– sequence: 3
  givenname: Florence
  surname: Morel
  fullname: Morel, Florence
– sequence: 4
  givenname: Nicolas
  surname: Veziris
  fullname: Veziris, Nicolas
– sequence: 5
  givenname: Emmanuel
  surname: Lecorché
  fullname: Lecorché, Emmanuel
– sequence: 6
  givenname: Faiza
  surname: Mougari
  fullname: Mougari, Faiza
– sequence: 7
  givenname: Claire
  surname: Andrejak
  fullname: Andrejak, Claire
– sequence: 8
  givenname: Anne
  surname: Bourgarit
  fullname: Bourgarit, Anne
– sequence: 9
  givenname: Elise
  surname: Klement
  fullname: Klement, Elise
– sequence: 10
  givenname: Bénédicte
  surname: Rivoire
  fullname: Rivoire, Bénédicte
– sequence: 11
  givenname: Guillaume
  surname: Thouvenin
  fullname: Thouvenin, Guillaume
– sequence: 12
  givenname: Simone
  surname: Tunesi
  fullname: Tunesi, Simone
– sequence: 13
  givenname: Marie
  surname: Wicky
  fullname: Wicky, Marie
– sequence: 14
  givenname: Marie
  surname: Jaspard
  fullname: Jaspard, Marie
– sequence: 15
  givenname: Corentine
  surname: Alauzet
  fullname: Alauzet, Corentine
– sequence: 16
  givenname: Lelia
  surname: Escaut
  fullname: Escaut, Lelia
– sequence: 17
  givenname: Sophie
  surname: Ellis-Corbet
  fullname: Ellis-Corbet, Sophie
– sequence: 18
  givenname: Christine
  surname: Bernard
  fullname: Bernard, Christine
– sequence: 19
  givenname: Anne-Laure
  surname: Roux
  fullname: Roux, Anne-Laure
Copyright The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Copyright_xml – notice: The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
CorporateAuthor LZDM group
CorporateAuthor_xml – name: LZDM group
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1093/cid/ciac485
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1537-6591
ExternalDocumentID 35717636
Genre Research Support, U.S. Gov't, Non-P.H.S
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
..I
.2P
.I3
.ZR
08P
0R~
29B
2WC
36B
4.4
48X
53G
5GY
5RE
5VS
5WD
6J9
70D
AABZA
AACGO
AACZT
AAJKP
AAMVS
AANCE
AAOGV
AAPNW
AAPQZ
AAPXW
AAQQT
AARHZ
AAUAY
AAVAP
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABOCM
ABPLY
ABPQP
ABPTD
ABQLI
ABQNK
ABTLG
ABVGC
ABWST
ABXVV
ABZBJ
ACGFO
ACGFS
ACPRK
ACUFI
ACUTO
ACYHN
ADBBV
ADEYI
ADGZP
ADHKW
ADHZD
ADIPN
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFIYH
AFOFC
AFRAH
AFXAL
AFYAG
AGINJ
AGKEF
AGQXC
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AIAGR
AIJHB
AJEEA
AJNCP
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
AQKUS
ATGXG
AXUDD
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CDBKE
CGR
CS3
CUY
CVF
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBS
ECM
EE~
EIF
EMOBN
ENERS
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
H13
H5~
HAR
HW0
HZ~
IOX
J21
JLS
JSG
JXSIZ
KAQDR
KOP
KSI
KSN
L7B
M49
MHKGH
MJL
ML0
N9A
NGC
NOMLY
NOYVH
NPM
NU-
O9-
OAUYM
OAWHX
OCZFY
ODMLO
ODZKP
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
P6G
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
RD5
ROX
ROZ
RUSNO
RW1
RXO
SJN
TCURE
TEORI
TJX
TMA
TR2
W8F
X7H
YAYTL
YKOAZ
YXANX
~91
~S-
7X8
AHGBF
AJBYB
ID FETCH-LOGICAL-c391t-71793e15a1cc4cdbf335babbca87244dc923b656164588a5f27a1940caa5acc12
IEDL.DBID 7X8
ISICitedReferencesCount 17
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000859896300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1537-6591
IngestDate Thu Oct 02 05:35:30 EDT 2025
Thu Apr 03 06:58:07 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords toxicity
severe adverse events
linezolid
multidrug-resistant tuberculosis
therapeutic drug monitoring
Language English
License The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c391t-71793e15a1cc4cdbf335babbca87244dc923b656164588a5f27a1940caa5acc12
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-3351-8581
OpenAccessLink https://hal.science/hal-03909796
PMID 35717636
PQID 2678424104
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2678424104
pubmed_primary_35717636
PublicationCentury 2000
PublicationDate 2023-02-08
PublicationDateYYYYMMDD 2023-02-08
PublicationDate_xml – month: 02
  year: 2023
  text: 2023-02-08
  day: 08
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Clinical infectious diseases
PublicationTitleAlternate Clin Infect Dis
PublicationYear 2023
SSID ssj0011805
Score 2.5055187
Snippet Treatment of multidrug-resistant (MDR) tuberculosis with linezolid is characterized by high rates of adverse events. Evidence on therapeutic drug monitoring to...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage e947
SubjectTerms Antitubercular Agents - adverse effects
Drug Monitoring
Humans
Linezolid - adverse effects
Retrospective Studies
Tuberculosis, Multidrug-Resistant - drug therapy
Title Association Between Increased Linezolid Plasma Concentrations and the Development of Severe Toxicity in Multidrug-Resistant Tuberculosis Treatment
URI https://www.ncbi.nlm.nih.gov/pubmed/35717636
https://www.proquest.com/docview/2678424104
Volume 76
WOSCitedRecordID wos000859896300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS-QwEA-eHocv6n34reTgXoPNNmnTJ1FRfNBl8faOfVuSyUQWtNXtrqh_hn-xk24XfTkQ7qXQ0tJ8zEx-k_llhrFfufKFdNqKBG1HKIdaFGC80AkEAwFU0WS8-XuRd7tmMCh67YZb3dIq5zaxMdS-grhHftAhq6pouUnU4d29iFWjYnS1LaHxiS2lBGWiVOeDtyiCNA2FkZQ6F5kuZHs-j5z4A6Cpps6DMvrf2LJZY85W_7d1a2ylRZf8aCYOX9kClt_Yl8s2fv6dvbybDX48o2hxMhGRmY6ek2OKz9XNyPMegepby0_iocayzaxbc1t6ToCRv2Ma8Srw33Q7Rt6vHuk3kyc-KnlzrtePp9fiCusIUenN_tThGKY3FT3g_TnB_Qf7c3baPzkXbVUGAWkhJyKPKo1SWwmgwLuQptpZ58CanLCCB4KMjlAi-WHaGKtDJ7eyUAlYqy2A7KyzxbIqcZPxNICxMpgkACqNaBAxCahRJi6TIdtiP-ejPSSpj6EMW2I1rYdv473FNmZTNrybpecYppqamKXZ9ge-3mHLsX58Q8M2u2wpkM7jHvsMD5NRPd5vxImu3d7lKz8T2vM
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+Between+Increased+Linezolid+Plasma+Concentrations+and+the+Development+of+Severe+Toxicity+in+Multidrug-Resistant+Tuberculosis+Treatment&rft.jtitle=Clinical+infectious+diseases&rft.au=Eimer%2C+Johannes&rft.au=Fr%C3%A9chet-Jachym%2C+Mathilde&rft.au=Le+D%C3%BB%2C+Damien&rft.au=Caumes%2C+Eric&rft.date=2023-02-08&rft.eissn=1537-6591&rft.volume=76&rft.issue=3&rft.spage=e947&rft_id=info:doi/10.1093%2Fcid%2Fciac485&rft_id=info%3Apmid%2F35717636&rft_id=info%3Apmid%2F35717636&rft.externalDocID=35717636
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-6591&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-6591&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-6591&client=summon